7707 Gateway Boulevard
United States - Map
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system. The company has completed Phase I/II clinical trial for the treatment of chronic spinal cord injury; and Phase I clinical trial for the treatment of Pelizaeus-Merzbacher disease, as well as completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration that cause blindness in the elderly. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.
|Mr. Martin M. McGlynn ,
Chief Exec. Officer, Director, Chief Exec. Officer of Stemcells California Inc, Pres of Stemcells California Inc and Member of Strategic Transactions Committee
|Dr. Ann Tsukamoto Ph.D.,
Exec. VP of Scientific & Strategic Alliances
|Dr. Ian John Massey DPhil,
Pres and Chief Operating Officer
|Mr. Gregory T. Schiffman MBA, CPA,
Chief Financial Officer and Exec. VP of Fin.
|Ms. Megan Meloni ,
Director of Investor Relations & Corp. Communications
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|